Nexalin Technology Inc. (NXL)
NASDAQ: NXLHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 3.87 -5.83%
NXL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.41M
- EPS (TTM)
- -$14.10
- Dividend yield
- None
- 52-week range
- 3.97 – 50.70
- Day range
- 3.98 – 4.34
- Volume / Avg
- 425.65K / 1.02M
- Beta
- —
- Shares outstanding
- 829.40K
52-week range
NXL stock today
Shares of Nexalin Technology (NXL) finished lower on Oct 8 at $4.11, a drop of 4.86% or $0.21 per share, versus the S&P 500's 0.47% decline. Trading was light, with 425.65K shares changing hands, about 42% of the average daily volume. At this level, NXL sits near the bottom of its 52-week range of $3.97 to $50.70: 91.9% below the high and 3.5% above the low.
Nexalin Technology has posted a net loss over the last twelve months (EPS of -$14.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nexalin Technology
Company profileNexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Mark White
- Headquarters
- Houston, TX
- Employees
- 8
- IPO year
- 2022
- Website
- nexalin.com
Analyst forecast
ForecastConsensus (1 analysts)
buy
Avg. price target
$15.00+264.96%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
NXL news
All NXL newsNexalin Technology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VBIOValion Bio Inc. | 2.21 | +0.91% | $4.30M | vs NXL |
| NUWENuwellis Inc. | 0.6751 | -1.92% | $2.46M | vs NXL |
| NDRAENDRA Life Sciences Inc. | 5.93 | -2.15% | $8.89M | vs NXL |
| IRIXIRIDEX Corporation | 0.898 | +2.24% | $15.77M | vs NXL |
| ITOCiTonic Holdings Ltd Class A | 4.02 | -3.13% | $29.41M | vs NXL |
| QTIQT Imaging Holdings Inc. | 2.60 | +1.17% | $38.05M | vs NXL |
| POCIPrecision Optics Corporation Inc. | 4.67 | +3.21% | $51.19M | vs NXL |
| OMOutset Medical Inc. | 4.09 | -2.85% | $76.88M | vs NXL |
Indexes, lists and sector
Nexalin Technology stock FAQ
What is Nexalin Technology's stock price today?
NXL last traded at $4.11 as of Oct 8, 4:00 PM EDT, down 4.86% on the day. Prices are delayed at least 15 minutes.
Who is Nexalin Technology's CEO?
Mr. Mark White is the chief executive officer of Nexalin Technology Inc., which has about 8 employees.
What is the NXL 52-week high?
The 52-week high for NXL is $50.70 and the 52-week low is $3.97. The stock is currently 91.9% below its high.